Mirodenafil - CAS 862189-95-5
Catalog number:
862189-95-5
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C26H37N5O5S
Molecular Weight:
531.67
COA:
Inquire
Targets:
Phosphodiesterase (PDE)
Description:
Mirodenafil is a newly developed oral phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction. It significantly improved erectile function and were well tolerated in a representative population of Korean men with broad-spectrum ED of various etiologies and severities.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
SK3530
MSDS:
Inquire
1.A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction.
Cho MC1, Paick JS2. Ther Adv Urol. 2016 Apr;8(2):100-17. doi: 10.1177/1756287215625408. Epub 2016 Jan 19.
Erectile dysfunction (ED) is a common disorder that can jeopardize quality of life and the partnership of patients and their sexual partners. The advent of oral phosphodiesterase type 5 inhibitors (PDE5Is) has revolutionized a treatment for ED, and they are recognized as the first-line therapy for ED, regardless of its etiology. Mirodenafil, a second-generation PDE5I, has biochemical profiles such as high affinity for PDE5 and high selectivity for PDE5 over other PDE isoforms, compared to other existing PDE5Is such as sildenafil, vardenafil and tadalafil. Available evidence has suggested that doses of 50 and 100 mg mirodenafil effectively improve ED [with improvements in the erectile function domain of the International Index of Erectile Function (IIEF-EF) scores, positive responses to questions 2 of the Sexual Encounter Profiles (SEP2) and questions 3 of the Sexual Encounter Profiles (SEP3): 7.6-11.6 points, 27.72-38.98% and 44.20-67.33%, respectively] in a broad range of patient populations with ED of a variety of underlying etiologies, severities and ages, without any serious treatment-related adverse effects.
2.Drug Concentration in Rat Plasma, Bladder, and Prostate After Mirodenafil Administration in a Chronic Pelvic Ischemia Model.
Shim JS1, Bae JH2. Urology. 2016 Feb 23. pii: S0090-4295(16)00186-2. doi: 10.1016/j.urology.2016.02.017. [Epub ahead of print]
OBJECTIVE: To evaluate the distribution of a daily phosphodiesterase type 5 inhibitor dose (mirodenafil) in rat plasma and bladder and prostate tissue in a model of atherosclerosis-induced chronic pelvic ischemia.
3.Impact of the change in urinary and sexual function on health-related quality of life after once daily low-dose mirodenafil treatment in patients with organic erectile dysfunction.
Lee DS1, Choe HS, Kim SW, Jung KU, Lee SJ. Urol Int. 2014;93(1):84-91. doi: 10.1159/000355360. Epub 2014 Jan 23.
OBJECTIVE: We aimed to evaluate whether changes in urinary and sexual function can influence health-related quality of life.
4.An LC-MS/MS method for the determination of five erectile dysfunction drugs and their selected metabolites in hair.
Lee S1, Choi B1, Kim J2, In S2, Baeck S2, Oh SM3, Chung KH4. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 26;978-979:1-10. doi: 10.1016/j.jchromb.2014.11.024. Epub 2014 Dec 5.
The abuse of sildenafil and its analogous, accelerated by their inappropriate or illegal distribution, is a serious social issue globally. However, no studies have been conducted to monitor these drugs simultaneously in hair, which can provide valuable information on chronic drug use. In the present study, an LC-MS/MS method was developed for the simultaneous determination in hair of five erectile dysfunction drugs having a high risk for abuse (mirodenafil, sildenafil, tadalafil, udenafil and vardenafil) and their selected metabolites (SK3541, desmethylsildenafil, DA8164 and desethylvardenafil). The novel method was fully validated after optimizing matrix effects and extraction efficiency. The optimized sample preparation included acidic methanol extraction followed by solid phase extraction using C18 mixed mode strong cation exchange polymeric cartridges. The prepared samples were analyzed by LC-MS/MS with electrospray ion source in the positive ionization mode.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products


CAS 81840-15-5 Vesnarinone

Vesnarinone
(CAS: 81840-15-5)

Vesnarinone, a quinolinone derivative, is a cardiotonic agent. It has pharmacodynamic effects include inhibition of phosphodiesterase III (PDE3) activity, incre...

CAS 330784-47-9 Avanafil

Avanafil
(CAS: 330784-47-9)

A phosphodiesterase (PDE5) inhibitor, used to treat erectile dysfunction.

CAS 85416-75-7 (R)-(-)-Rolipram

(R)-(-)-Rolipram
(CAS: 85416-75-7)

(R)-(-)-Rolipram is a potent and cAMP-specific PDE4 inhibitor. It is 2.5-fold more potent than (+)-rolipram in inhibiting membrane-bound PDE 4.

CAS 898563-00-3 TP-10

TP-10
(CAS: 898563-00-3)

TP-10 is a PDE10A inhibitor with IC50 of 0.8 nM. It has extremely potent PDE10A inhibitory activity and high selectivity against other PDEs. It is active in the...

CAS 1013750-77-0 ML-030

ML-030
(CAS: 1013750-77-0)

ML-030, a triazolothiadiazine, is a potent PDE4 inhibitor in a cell-based cyclic nucleotide-gated cation channel biosensor assay (EC50 = 18.7 nM), with IC50 of ...

CAS 224789-15-5 Vardenafil dihydrochloride

Vardenafil dihydrochloride
(CAS: 224789-15-5)

Vardenafil, also called as Levitra and Nuviva, is a phosphodiesterase inhibitor that is selective for PDE5 and PDE1 (IC50 = 0.7 and 180 nM, respectively).

CI-1018
(CAS: 245329-99-1)

CI-1018 is a selective type 4 phosphodiesterase inhibitor associated with vasculitis. CI-1018 has been in development to suppress inflammation.

CAS 171599-83-0 Sildenafil Citrate

Sildenafil Citrate
(CAS: 171599-83-0)

Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective tr...

CAS 439083-90-6 Bay 60-7550

Bay 60-7550
(CAS: 439083-90-6)

Bay 60-7550 is a potent PDE2 inhibitor. It is 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5 PDE3B, PDE4B...

CAS 1238697-26-1 TAK-063

TAK-063
(CAS: 1238697-26-1)

TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for t...

ITI214
(CAS: 1642303-38-5)

ITI214 is a highly selective PDE1 inhibitor (Ki = 58 pM) at picomolar concentration without disrupting other PDE family members and a panel of enzymes, receptor...

CP-461 free base
(CAS: 227619-92-3)

CP 461, belonging to a class of novel proapoptotic drugs with antineoplastic effect, specifically inhibit cyclic GMP phosphodiesterases but not cyclooxygenase-1...

CAS 119615-63-3 Olprinone Hydrochloride

Olprinone Hydrochloride
(CAS: 119615-63-3)

Olprinone is a selective phosphodiesterase 3 (PDE3) inhibitor. Olprinone is used as cardiotonic agent with positive inotropic and vasodilating effects. Olprinon...

CAS 106730-54-5 Olprinone

Olprinone
(CAS: 106730-54-5)

Olprinone(Loprinone) is a selective phosphodiesterase 3 (PDE3) inhibitor.

CAS 268203-93-6 Udenafil

Udenafil
(CAS: 268203-93-6)

Udenafil is an oral PDE5 inhibitor. Udenafil significantly increased cAMP and cGMP levels and were more highly distributed in the prostate than plasma. The T/P ...

CAS 862189-95-5 Mirodenafil

Mirodenafil
(CAS: 862189-95-5)

Mirodenafil is a newly developed oral phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction. It significantly improved ...

LEO29102
(CAS: 1035572-38-3)

LEO29102 is a potent, selective, and soft-drug phosphodiesterase 4 (PDE4) inhibitor. It shows properties suitable for patient-friendly formulations giving effic...

CAS 141184-34-1 Filaminast

Filaminast
(CAS: 141184-34-1)

Filaminast is a Type 4 cyclic nucleotide phosphodiesterase inhibitor. It is an analog of rolipram which served as a prototype molecule for several development e...

CAS 939055-18-2 FIPI

FIPI
(CAS: 939055-18-2)

FIPI, a derivative of halopemide, is a potent and selective phospholipase D (PLD) inhibitor with IC50 values of 20 and 25 nM for PLD2 and PLD1 respectively. It ...

CAS 898562-94-2 PF-2545920

PF-2545920
(CAS: 898562-94-2)

PF-2545920 a highly selective and potent PDE10A inhibitor. It was active with an ED50 of 1 mg/kg.

Chemical Structure

CAS 862189-95-5 Mirodenafil

Quick Inquiry

Verification code

Featured Items